These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 568738)

  • 41. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 42. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.
    Zarrindast MR; Poursoltan M
    Br J Pharmacol; 1989 Apr; 96(4):843-8. PubMed ID: 2663110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154).
    Di Chiara G; Porceddu ML; Vargiu L; Gessa GL
    Pharmacology; 1978; 16 Suppl 1():135-42. PubMed ID: 643899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
    Koller WC; Herbster G
    Neurology; 1987 Apr; 37(4):723-7. PubMed ID: 3561789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time course of dopaminergic hypersensitivity following chronic narcotic treatment.
    Carlson KR; Almasi J
    Pharmacol Biochem Behav; 1979 Sep; 11(3):283-7. PubMed ID: 574284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Behavioral changes in 6-hydroxydopamine-treated rotation rats after delivery of various neuromodifying agents by means of a stereotactically implanted pellet to the brain.
    Yoshida M; Torigoe R; Ohtsuru K; Kuramoto S
    Stereotact Funct Neurosurg; 1990; 54-55():342-6. PubMed ID: 2127860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clonazepam and dopamine-related stereotyped behavior.
    Weiner WJ; Goetz C; Nausleda PA; Klawans HL
    Life Sci; 1977 Oct; 21(7):901-6. PubMed ID: 562960
    [No Abstract]   [Full Text] [Related]  

  • 49. Sensitivity to apomorphine in the guinea pig as a function of age and body weight.
    Carlson KR; Almasi J
    Psychopharmacology (Berl); 1978 May; 57(3):279-82. PubMed ID: 97709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced stereotypies after repeated injections but not continuous amphetamines.
    Nelson LR; Ellison G
    Neuropharmacology; 1978 Dec; 17(12):1081-4. PubMed ID: 570650
    [No Abstract]   [Full Text] [Related]  

  • 51. Pemoline-induced chorea.
    Nausieda PA; Koller WC; Weiner WJ; Klawans HL
    Neurology; 1981 Mar; 31(3):356-60. PubMed ID: 7193830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Involvement of serotoninergic neurons in the hyperthermic response to dopaminergic agonists.
    Carruba MO; Tofanetti O; Picotti GB; Mantegazza P
    Pharmacol Res Commun; 1978 Apr; 10(4):357-70. PubMed ID: 150605
    [No Abstract]   [Full Text] [Related]  

  • 53. Bromocriptine in parkinsonism.
    Marsden CD; Parkes JD
    Lancet; 1976 Aug; 2(7982):419-20. PubMed ID: 73879
    [No Abstract]   [Full Text] [Related]  

  • 54. Videotaping: the evaluation of stereotypic effects of antiparkinsonian agents.
    Wilcox RE; Riffee WH; Smith RV
    Pharmacol Biochem Behav; 1979 Jan; 10(1):161-4. PubMed ID: 571607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dopamine agonist therapy for neglect in humans.
    Fleet WS; Valenstein E; Watson RT; Heilman KM
    Neurology; 1987 Nov; 37(11):1765-70. PubMed ID: 3670614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bromocriptine: decreased clinical effects at higher dosages.
    Koller WC; Weiner WJ; Nausieda PA; Klawans HL
    Neurology; 1979 Oct; 29(10):1439-40. PubMed ID: 573399
    [No Abstract]   [Full Text] [Related]  

  • 57. The stress-dependent nature of apomorphine hyperthermia.
    Snow AE; Horita A
    Brain Res; 1976 Nov; 117(1):163-8. PubMed ID: 1033021
    [No Abstract]   [Full Text] [Related]  

  • 58. Initial bromocriptine did not change mortality in early, mild Parkinson disease.
    Albanese A
    ACP J Club; 2002; 136(3):109. PubMed ID: 11985450
    [No Abstract]   [Full Text] [Related]  

  • 59. Lack of cross-sensitization between the locomotor-activating effects of bromocriptine and those of cocaine or heroin.
    Hoffman DC; Wise RA
    Psychopharmacology (Berl); 1993; 110(4):402-8. PubMed ID: 7870909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
    Globus M; Bannet J; Lerer B; Belmaker RH
    Psychopharmacology (Berl); 1982; 78(1):81-4. PubMed ID: 6815701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.